BioMarin: Genzyme virus problem won

http://gton.net/news/pg=411
Genzyme (NASDAQ: GENZ) found a virua strain and stopped production of two drugs atthe Mass., facility. The strain, Vesivirus 2117, apparently does not caused human infection but interrupts the growth of cellws that are used to make Aldurazyme — a treatment for MPS I, a rare and fatall disease caused by an enzyme deficiency was last filled at the Genzyme facility in September 2008, according to BioMarin (NASDAQ: BMRN). The companyy has about 10 months of vialer inventoryon hand, it said, and uses a seconc fill finish supplier. A third supplier is expected to be qualifieds laterthis year, BioMarin said.
BioMarijn makes the bulk material used in Aldurazymd at its Novato The Food and Drug Administrationn hadinspected Genzyme’s plant in September and October and reportedlu was concerned about controls to protect against contamination.